Biomea Fusion, Inc.
Small-molecule therapeutics targeting immune and inflammatory diseases
- Sector
- Biotech
- Headquarters
- Redwood City, CA
- Founded
- 2017
- Latest Form D
- $56M, Jan 2021
- Total capital
- $56M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $56M
- 1 Form D · last Jan 2021
- 69 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2023
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$56M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ramses ErdtmannDirector, Executive OfficerNamed in SEC Form D filings
- Thomas ButlerExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- GrantedHeterocyclic GLP-1R AgonistsUSPTOUS 12,617,783
- PendingFused Pyrimidine Compounds As Inhibitors Of MeninUSPTOApplication 18871252
- PendingFlt Combination Therapy For Cancer And Compositions ThereforUSPTOApplication 18865235
Show all 40 patent records
- Heterocyclic GLP-1R AgonistsMay 5, 2026 · US 12,617,783Granted
- Fused Pyrimidine Compounds As Inhibitors Of MeninNov 20, 2025 · Application 18871252Pending
- Flt Combination Therapy For Cancer And Compositions ThereforOct 9, 2025 · Application 18865235Pending
- Covalent Inhibitors Of Menin-mll Interaction For Diabetes MellitusMay 22, 2025 · Application 18926210Pending
- Pyrazine Compounds As Irreversible Inhibitors Of FLT3May 1, 2025 · Application 18685076Pending
- Inhibitors Of Menin-mll InteractionApr 15, 2025 · US 12,275,739Granted
- Covalent Inhibitors Of Menin-mll Interaction For Diabetes MellitusMar 18, 2025 · US 12,251,385Granted
- Inhibitors Of KrasFeb 27, 2025 · Application 18690517Pending
- CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDEFeb 4, 2025 · US 12,215,113Granted
- CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE AS IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTIONDec 19, 2024 · Application 18810281Pending
- Irreversible Inhibitors Of KrasDec 12, 2024 · Application 18690830Pending
- N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOFNov 14, 2024 · Application 18768954Pending
- Crystalline Forms Of An Irreversible Inhibitor Of Menin-mll InteractionOct 17, 2024 · Application 18437153Pending
- Substituted Pyridines As Irreversible Inhibitors Of Menin-mll InteractionOct 15, 2024 · US 12,116,371Granted
- Irreversible Inhibitors Of Menin-mll InteractionSep 3, 2024 · US 12,077,544Granted
- Substituted Pyrazines As Inhibitors Of FLT3Aug 8, 2024 · Application 18440293Pending
- CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE AS AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTIONJun 25, 2024 · US 12,018,032Granted
- Fused Pyrimidine Compounds As Inhibitors Of Menin-mll InteractionApr 18, 2024 · Application 18257541Pending
- Pyrazine Compounds As Inhibitors Of FLT3Apr 2, 2024 · US 11,945,785Granted
- Inhibitors Of Menin-mll InteractionDec 19, 2023 · US 11,845,753Granted
- Fused Pyrimidine Compounds As Inhibitors Of MeninApplication 63515973Pending
- Menin-mll Inhibitors And Compositions For Proliferation Of Beta CellsApplication PCTUS2023026503Pending
- Fused Pyrimidine Compounds As Inhibitors Of MeninApplication PCTUS2023024381Pending
- Fused Pyrimidine Compounds As Inhibitors Of MeninApplication 63505848Pending
- FLT3 Combination Therapy For Cancer And Compositions ThereforApplication PCTUS2023022402Pending
- Crystalline Forms Of A Covalent Inhibitor Of Menin-mll InteractionApplication 63492404Pending
- Crystalline Forms Of A Covalent Inhibitor Of Menin-mll InteractionApplication 63486405Pending
- Crystalline Forms Of A Covalent Inhibitor Of Menin-mll InteractionApplication 63483648Pending
- Crystalline Forms Of A Covalent Inhibitor Of Menin-mll InteractionApplication 63480443Pending
- Pyrazine Compounds As Inhibitors Of FLT3Application PCTUS2022054270Pending
- Pyrazine Compounds As Inhibitors Of FLT3Application 63386772Pending
- Inhibitors Of KrasApplication PCTUS2022049314Pending
- INHIBITORS OF KRasApplication 63376234Pending
- Irreversible Inhibitors Of KrasApplication PCTUS2022043203Pending
- Pyrazine Compounds As Irreversible Inhibitors Of FLT3Application PCTUS2022040953Pending
- Covalent Inhibitors Of Menin-mll Interaction For Diabetes MellitusApplication PCTUS2022039990Pending
- Crystalline Forms Of An Irreversible Inhibitor Of Menin-mll InteractionApplication PCTUS2022039941Pending
- Menin-mll Inhibitors And Compositions For Proliferation Of Beta CellsApplication 63356393Pending
- Fused Pyrimidine Compounds As Inhibitors Of Menin-mll InteractionApplication 63348607Pending
- Substituted Pyrazine Compounds As Irreversible Inhibitors Of FLT3Application 63364860Pending
Related companies, and why
- SUPERNUS PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Siolta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- PEPTIDE LOGIC LLCSimilar federal contract value in Biotech · null in contracts
- Azitra Inc.Similar federal contract value in Biotech · null in contracts
- Molecular Assemblies, Inc.Similar federal contract value in Biotech · null in contracts
- Cyrus Biotechnology, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .